Multiple myeloma (MM) is a B-cell malignancy characterized ... As the distribution of the clinical parameters and the percentage of MYC staining cells was not statistically different between ...

Multiple myeloma (MM) is an incurable malignancy of bone marrow plasma cells characterized by wide clinical and molecular heterogeneity. In this study we applied an integrative network biology ...

4, 2024 — A new study shows strong alignment between real-world outcomes and those seen in clinical trials among a broad population of patients with relapsed or refractory multiple myeloma.

There are three stages of multiple myeloma, and the stage you receive at diagnosis gives an overall picture of how far the disease has progressed and helps inform treatment decisions. Your ...

Here Dr. Usmani discusses the current outlook for the disease and his vision for developing new treatment approaches at MSK that will improve multiple myeloma prognosis (outcome). This includes very ...

This review summarizes the mechanisms of action and clinical activity of IMiDs in MM. Multiple myeloma (MM) is a malignant plasma cell disorder accounting for approximately 10% of all hematologic ...

Survival of patients with multiple ... HRMM in clinical trials, it enables better comparability of therapeutic outcomes and guides the development of targeted interventions for this high-risk group.* ...

D.K.H, L.C.P., L.B.O., M.A., and C.L.F. are supported by the Pentecost Family Myeloma Research Center. This work was in part supported by the Moffitt Cancer Center National Cancer Center Institute ...